EcoDrugPlus

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSDCDG00000026468
Gene Symbol: LOC114763869
3 Cross references
172 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSDCDG00000029286
Gene Symbol: LOC114785364
3 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSDCDG00000014251
Gene Symbol: LOC114799295
3 Cross references
202 Possible Orthologues:

Prostaglandin G/h Synthase 1-Like

Ensembl ID : ENSDCDG00000000457
Gene Symbol: LOC114787947
3 Cross references
196 Possible Orthologues:

Prostaglandin G/h Synthase 2-Like

Ensembl ID : ENSDCDG00000029712
Gene Symbol: LOC114769344
3 Cross references
212 Possible Orthologues:

Prostaglandin G/h Synthase 2-Like

Ensembl ID : ENSDCDG00000030400
Gene Symbol: LOC114768818
3 Cross references
212 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSDCDG00000034939
Gene Symbol: PTGIR
3 Cross references
188 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSDCDG00000034377
Gene Symbol: PSMA1
3 Cross references
271 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSDCDG00000021216
Gene Symbol: PSMA2
2 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSDCDG00000028622
Gene Symbol: PSMA2
3 Cross references
257 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSDCDG00000001830
Gene Symbol: PSMA3
3 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSDCDG00000035114
Gene Symbol: PSMA4
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).